ValuEngine upgraded shares of Cerulean Pharma (NASDAQ:DARE) from a strong sell rating to a sell rating in a report published on Saturday morning.

Cerulean Pharma (DARE) opened at $2.54 on Friday. Cerulean Pharma has a 12 month low of $2.24 and a 12 month high of $35.80.

WARNING: “Cerulean Pharma (DARE) Upgraded to “Sell” by ValuEngine” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/13/cerulean-pharma-dare-upgraded-to-sell-by-valuengine.html.

Cerulean Pharma Company Profile

Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Cerulean Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma and related stocks with our FREE daily email newsletter.